FR2702659B1 - Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine. - Google Patents

Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.

Info

Publication number
FR2702659B1
FR2702659B1 FR9303230A FR9303230A FR2702659B1 FR 2702659 B1 FR2702659 B1 FR 2702659B1 FR 9303230 A FR9303230 A FR 9303230A FR 9303230 A FR9303230 A FR 9303230A FR 2702659 B1 FR2702659 B1 FR 2702659B1
Authority
FR
France
Prior art keywords
muramyl
cytokine
peptide
association
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR9303230A
Other languages
French (fr)
Other versions
FR2702659A1 (en
Inventor
Chedid Louis
Bahr Georges
Lefrancier Pierre
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vacsyn SA
Original Assignee
Vacsyn SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR9303230A priority Critical patent/FR2702659B1/en
Application filed by Vacsyn SA filed Critical Vacsyn SA
Priority to PCT/FR1994/000307 priority patent/WO1994021275A1/en
Priority to ES94910445T priority patent/ES2187520T3/en
Priority to EP94910445A priority patent/EP0689449B1/en
Priority to PT94910445T priority patent/PT689449E/en
Priority to AT94910445T priority patent/ATE226828T1/en
Priority to DE69431620T priority patent/DE69431620T2/en
Priority to JP52072694A priority patent/JP3723206B2/en
Priority to AU62856/94A priority patent/AU6285694A/en
Priority to CA002157758A priority patent/CA2157758A1/en
Priority to DK94910445T priority patent/DK0689449T3/en
Priority to US08/522,342 priority patent/US5932208A/en
Publication of FR2702659A1 publication Critical patent/FR2702659A1/en
Application granted granted Critical
Publication of FR2702659B1 publication Critical patent/FR2702659B1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Zoology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FR9303230A 1993-03-19 1993-03-19 Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine. Expired - Fee Related FR2702659B1 (en)

Priority Applications (12)

Application Number Priority Date Filing Date Title
FR9303230A FR2702659B1 (en) 1993-03-19 1993-03-19 Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.
AU62856/94A AU6285694A (en) 1993-03-19 1994-03-21 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
EP94910445A EP0689449B1 (en) 1993-03-19 1994-03-21 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
PT94910445T PT689449E (en) 1993-03-19 1994-03-21 COMPOSITIONS FOR APPLICATION IN HUMAN THERAPEUTICS CHARACTERIZED BY THE ASSOCIATION OF A MURAMILO PEPTIDE TO A CITOQUIN
AT94910445T ATE226828T1 (en) 1993-03-19 1994-03-21 COMPOSITIONS FOR USE IN HUMAN THERAPY CHARACTERIZED BY THE ASSOCIATION OF A MURAMYL PEPTIDE WITH A CYTOKINE
DE69431620T DE69431620T2 (en) 1993-03-19 1994-03-21 COMPOSITIONS FOR USE IN HUMAN THERAPY, CHARACTERIZED BY ASSOCIATING A MURAMYL PEPTIDE WITH A CYTOKIN
PCT/FR1994/000307 WO1994021275A1 (en) 1993-03-19 1994-03-21 Therapeutical compositions for use in humans, characterised by a combination of a muramyl peptide and a cytokine
ES94910445T ES2187520T3 (en) 1993-03-19 1994-03-21 COMPOSITIONS FOR APPLICATION IN HUMAN THERAPEUTICS, CHARACTERIZED BY THE ASSOCIATION OF A MURAMIL-PEPTIDE TO A CYTOQUINE.
CA002157758A CA2157758A1 (en) 1993-03-19 1994-03-21 Compositions for use in human therapeutics, characterised by the association of a muramyl peptide with a cytokine
DK94910445T DK0689449T3 (en) 1993-03-19 1994-03-21 Preparations for use in human therapy, characterized by combining a muramyl peptide with a cytokine
US08/522,342 US5932208A (en) 1993-03-19 1994-03-21 Compositions and methods for the use of such compositions in human therapeutics, characterized by the association of a muramyl peptide with a cytokine
JP52072694A JP3723206B2 (en) 1993-03-19 1994-03-21 A therapeutic composition for use in humans, characterized by combining muramyl peptide and cytokine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR9303230A FR2702659B1 (en) 1993-03-19 1993-03-19 Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.

Publications (2)

Publication Number Publication Date
FR2702659A1 FR2702659A1 (en) 1994-09-23
FR2702659B1 true FR2702659B1 (en) 1995-08-25

Family

ID=9445178

Family Applications (1)

Application Number Title Priority Date Filing Date
FR9303230A Expired - Fee Related FR2702659B1 (en) 1993-03-19 1993-03-19 Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.

Country Status (1)

Country Link
FR (1) FR2702659B1 (en)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK585886A (en) * 1985-12-24 1987-06-25 Takeda Chemical Industries Ltd IMMUNSTIMENTAL AGENTS AND USE THEREOF
IL83350A0 (en) * 1986-08-13 1987-12-31 Takeda Chemical Industries Ltd Pharmaceutical compositions comprising interleukin and intterferon active substances
GB8803365D0 (en) * 1988-02-13 1988-03-16 Ciba Geigy Ag Antiviral combination

Also Published As

Publication number Publication date
FR2702659A1 (en) 1994-09-23

Similar Documents

Publication Publication Date Title
ITRM910696A1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE NASAL APPLICATION.
FR2705566B1 (en) New pharmaceutical compositions.
NO954694D0 (en) Dosage form for antidepressants
FR2676256B1 (en) DRIVE UNIT FOR DUAL FAN.
EP0847757A4 (en) Medicine comprising hgf gene
FR2712666B1 (en) Luminaire for medical application.
IT1212778B (en) PHARMACEUTICAL COMPOSITIONS ANTI-INFLAMMATORY AND / OR ANALGESIC ADAPTERITY, NON ULCEROGENE.
CA2192480A1 (en) Benzopyrans and their use as therapeutic agents
DE58902899D1 (en) 2 ', 3'-DIDEOXYPURINNUCLEOSIDE / PURINNUCLEOSIDE-PHOSPHORYLASE INHIBITOR COMBINATION THERAPY AND COMPOSITIONS THEREFOR.
ITTO930866A0 (en) PROCEDURE AND MACHINE FOR THE MANUFACTURE OF COVERS FOR BOOKS AND THE SIMILAR, AND COVERS SO MADE.
FR2703251B3 (en) Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.
FR2695297B1 (en) Disinfectant agent composition.
FR2702659B1 (en) Compositions for application in human therapy, characterized by the association of a muramyl-peptide with a cytokine.
FR2686251B1 (en) COMPOSITION FOR THE HEALING OF A WOUND.
DE69201478D1 (en) Wear-resistant eutectic aluminum-silicon alloy.
ITRM920535A1 (en) PHARMACEUTICAL COMPOSITION FOR ADMINISTRATION THROUGH THE MUCOSES.
ITTO920793A1 (en) CURING MATURATOR FOR PROVOLONE AND SIMILAR.
FR2697436B1 (en) Adjustable ring softener for gymnastics.
ITRM930338A0 (en) BINDER FOR INSTRUCTIONS FOR THE USE OF ORGANIZATION MEANS.
IT8819447A0 (en) COMPOSITION OF COMPOUNDS THAT IMPROVE THE ANALGESIC, ANTIPYRETIC AND ANTI-INFLAMMATORY ACTIVITY.
ATE82855T1 (en) 2',3'-DIDEOXYPURINUCLEOSIDE/PURINUCLEOSIDPHOSPHORYLASE COMBINATION THERAPY INHIBITOR AND COMPOSITIONS THEREOF.
FR2685204B1 (en) PHARMACEUTICAL COMPOSITIONS FOR THE TRANSCUTANEOUS ADMINISTRATION OF FENFLURAMINE.
ITRM920498A1 (en) COMPOSITION FOR THE FIREPROOFING OF POLYMER MATERIALS.
FR2693103B1 (en) Stomatologist's furniture.
Leske Business curriculum as context: the lived experience of women

Legal Events

Date Code Title Description
ER Errata listed in the french official journal (bopi)

Free format text: 38/94

ST Notification of lapse

Effective date: 20061130